As filed with the Securities and Exchange Commission on March 10, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM S-8
REGISTRATION STATEMENT UNDER THE Securities Act of 1933
______________________
KALVISTA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
20-0915291 |
(State or Other Jurisdiction |
|
(I.R.S. Employer |
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901E
Cambridge, MA 02142
(Address of Principal Executive Offices) (Zip Code)
2017 Equity Incentive Plan
2017 Employee Stock Purchase Plan
(Full Title of the Plans)
Thomas Andrew Crockett
Chief Executive Officer
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901E
Cambridge, MA 02142
(Name and Address of Agent For Service)
(857) 999-0075
(Telephone Number, including area code, of agent for service)
Copies to:
Robert A. Freedman, Esq.
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, California 94041
(650) 988-8500
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☒ |
Non-accelerated filer ☐
|
Smaller reporting company ☒ |
|
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
To Be Registered |
Amount To Be |
Proposed Maximum Offering Price |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee |
Common Stock, $0.001 par value per share, reserved for future issuance pursuant to: |
|
|
|
|
- the 2017 Equity Incentive Plan |
713,704(2) |
$12.90(4) |
$9,206,781.60 |
$1,195.04 |
- the 2017 Employee Stock Purchase Plan |
178,425(3) |
$10.97(5) |
$1,957,322.25 |
$254.06 |
Total |
892,129 |
|
$11,164,103.85 |
$1,449.10 |
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock. |
(2) |
Represents additional shares of common stock reserved for issuance under the Registrant’s 2017 Equity Incentive Plan (the “2017 EIP”) resulting from the automatic annual increase in the number of authorized shares reserved for issuance under the 2017 EIP. The increase was effective as of January 1, 2020. |
(3) |
Represents additional shares of common stock reserved for issuance under the Registrant’s 2017 Employee Stock Purchase Plan (the “2017 ESPP”) resulting from the automatic annual increase in the number of authorized shares reserved for issuance under the 2017 ESPP. The increase was effective as of January 1, 2020. |
(4) |
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (h) under the Securities Act of 1933, as amended, based on the average of the high and low prices of the Registrant’s common stock as reported by the Nasdaq Global Market on March 6, 2020. |
(5) |
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (h) under the Securities Act of 1933, as amended, based on the average of the high and low prices of the Registrant’s common stock as reported by the Nasdaq Global Market on March 6, 2020, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2017 ESPP. |
STATEMENT PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8
REGISTRATION OF ADDITIONAL SECURITIES
This registration statement (the “Registration Statement”) hereby incorporates by reference the contents of the earlier registration statements on Form S-8 (registration numbers 333-230279, 333-226442, and 333-217008) filed with the Securities and Exchange Commission (the “Commission”) by KalVista Pharmaceuticals, Inc.
PART II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:
|
(a) |
The Registrant’s Annual Report on Form 10-K for the fiscal year ended April 30, 2019, filed with the Commission on July 16, 2019; |
|
|
(b) |
The Registrant’s Quarterly Reports on Form 10-Q for the three months ended July 31, 2019, October 31, 2019 and January 31, 2020, filed with the Commission on September 9, 2019, December 3, 2019 and March 10, 2020, respectively; |
|
|
(c) |
The Registrant’s Current Reports on Form 8-K filed with the Commission on July 1, 2019 and October 3, 2019; |
|
|
(d) |
All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and |
|
|
(e) |
The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (registration number 001-36830) filed with the Commission on February 2, 2015 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description. |
|
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.
Exhibit |
|
Incorporated by Reference |
Filed |
|||
Number |
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date |
Herewith |
5.1 |
|
|
|
|
|
X |
|
|
|
|
|
|
|
23.1 |
Consent of Deloitte & Touche LLP, independent registered public accounting firm. |
|
|
|
|
X |
|
|
|
|
|
|
|
23.2 |
|
|
|
|
X |
|
|
|
|
|
|
|
|
24.1 |
Power of Attorney (included on the signature page to this Registration Statement). |
|
|
|
|
X |
|
|
|
|
|
|
|
99.1 |
DEF 14A |
001-36830 |
Appendix A |
March 2, 2017 |
|
|
|
|
|
|
|
|
|
99.2 |
DEF 14A |
001-36830 |
Appendix B |
March 2, 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit |
|
Incorporated by Reference |
Filed |
|||
Number |
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date |
Herewith |
Forms of Equity Award Agreements under the 2017 Equity Incentive Plan. |
8-K |
001-36830 |
99.1 |
June 29, 2018 |
|
|
|
|
|
|
|
|
|
99.4 |
Enrollment/Change Form under the 2017 Employee Stock Purchase Plan. |
|
|
|
|
X |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of Massachusetts, on March 10, 2020.
KALVISTA PHARMACEUTICALS, INC.
By: /s/ T. Andrew Crockett
T. Andrew Crockett
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Thomas Andrew Crockett and Benjamin L. Palleiko, and each of them, with full power of substitution, such person’s true and lawful attorneys-in-fact and agents for such person, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature |
Title |
Date |
/s/ T. Andrew Crockett |
Chief Executive Officer and Director |
March 10, 2020 |
/s/ Benjamin L. Palleiko |
Chief Business Officer and Chief Financial Officer |
March 10, 2020 |
/s/ Albert Cha, M.D., Ph.D. |
Director |
March 10, 2020 |
/s/ Martin Edwards, M.D. |
Director |
March 10, 2020 |
/s/ Arnold L. Oronsky, Ph.D. |
Director |
March 10, 2020 |
/s/ Brian J. G. Pereira, M.D. |
Director |
March 10, 2020 |
Director |
March 10, 2020 |
|
/s/ Edward W. Unkart |
Director |
March 10, 2020 |
Exhibit 5.1
March 10, 2020
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901E
Cambridge, MA 02142
Ladies and Gentlemen:
At your request, as your counsel, we have examined the Registration Statement on Form S-8 (the "Registration Statement") to be filed by KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”) with the Securities and Exchange Commission (the "Commission") on or about March 10, 2020 in connection with the registration under the Securities Act of 1933, as amended (the “Securities Act”), of an aggregate of 892,129 shares (the “Shares”) of the Company’s Common Stock, $0.001 par value per share (the "Common Stock"), subject to issuance by the Company (a) upon the exercise or settlement of equity awards granted or to be granted under the Company’s 2017 Equity Incentive Plan, as amended to date (the “2017 EIP”) and (b) pursuant to purchase rights granted or to be granted under the Company’s 2017 Employee Stock Purchase Plan, as amended to date (the “2017 ESPP”). The 2017 EIP and the 2017 ESPP are each individually referred to herein as a “Plan” and collectively as the “Plans”.
At your request we are providing this letter to express our opinion on the matters set forth below in this letter (“our opinion”).
In connection with our opinion, we have examined such matters of fact as we have deemed necessary, which included examination of originals or copies of: the Company’s current Certificate of Incorporation and Bylaws, as amended (collectively, the “Charter Documents”), the Plans, the Registration Statement and the exhibits thereto; certain corporate proceedings of the Company’s Board of Directors (the “Board”), the Compensation Committee of the Board and the Company’s stockholders relating to adoption or approval of the Company Charter Documents, the Plans, the reservation of the Shares for sale and issuance, the filing of the Registration Statement and the registration of the Shares under the Securities Act and documents (including a certificate from the Company’s transfer agent) regarding the Company’s outstanding and reserved capital stock and other securities and such other documents as we have deemed advisable, and we have examined such questions of law as we have considered necessary.
In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the authenticity and completeness of all documents submitted to us as originals, the genuineness of signatures on documents reviewed by us, the conformity to originals and the completeness of all documents submitted to us as copies, the legal capacity of all parties executing any documents (other than the Company), the lack of any undisclosed termination or modification or waiver of any
document, the absence of any extrinsic agreements or documents that might change or affect the interpretation or terms of documents, and the due authorization, execution and delivery of all documents by each party thereto other than the Company. We have also assumed that any certificates or instruments representing the Shares, when issued, will be executed by the Company by officers of the Company duly authorized to do so. In rendering our opinion, we have also relied upon a Certificate of Good Standing dated March 9, 2020 issued by the Delaware Secretary of State with respect to the Company and representations and certifications made to us by the Company, including without limitation representations in a Management Certificate addressed to us of even date herewith that the Company has available a sufficient number of authorized shares of Common Stock that are not currently outstanding or reserved for issuance under other outstanding securities or plans of the Company, to enable the Company to issue and deliver all of the Shares as of the date of this letter.
We render this opinion only with respect to, and we express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the existing Delaware General Corporation Law now in effect. We express no opinion with respect to the securities or “blue sky” laws of any state.
Based upon, and subject to, the foregoing, it is our opinion that when the 892,129 Shares of Common Stock that may be issued and sold by the Company (a) upon the exercise or settlement of awards granted or to be granted under the 2017 EIP and (b) pursuant to purchase rights granted or to be granted under the 2017 ESPP, have been issued and sold by the Company against the Company’s receipt of payment therefor (in an amount and type of consideration not less than the par value per Share) in accordance with the terms (including without limitation payment and authorization provisions) of the applicable Plan, and have been duly registered on the books of the transfer agent and registrar for the Shares in the name or on behalf of the holders thereof, such Shares will be validly issued, fully paid and non-assessable.
[Signature page follows]
We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the prospectuses constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder. This opinion is intended solely for use in connection with issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.
Very truly yours,
/s/ Fenwick & West LLP
FENWICK & WEST LLP
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statements on Form S-8 of our report dated July 15, 2019 relating to the financial statement of KalVista Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2019.
/s/ DELOITTE & TOUCHE LLP
Boston, Massachusetts
March 10, 2020
Exhibit 99.4
KalVista Pharmaceuticals, Inc. (the “Company”) 2017 Employee Stock Purchase Plan |
Enrollment/Change Form
|
2
3
4
5
KalVista Pharmaceuticals, Inc.
2017 Employee Stock Purchase Plan
Global Enrollment/Change Form
Capitalized terms used but not defined herein shall have the meanings ascribed to them in the KalVista Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan ESPP (“ESPP”) or the Enrollment/Change Form to which this Appendix is attached.
Terms and Conditions
This Appendix includes additional terms and conditions that govern your participation in the ESPP if you reside and/or work in one of the countries listed below. If you are a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which you are currently residing and/or working, or if you transfer to another country after enrolling in the ESPP, the Company shall, in its discretion, determine to what extent the special terms and conditions contained herein shall be applicable to you.
Notifications
This Appendix also includes information regarding securities, exchange controls, tax and certain other issues of which you should be aware with respect to your participation in the ESPP. The information is based on the securities, exchange control, tax and other laws in effect in your country as of January 2019. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the ESPP because the information may be out of date at the time you exercise your right to purchase shares or sell shares of Common Stock purchased under the ESPP.
In addition, the information contained herein is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country, or are considered resident of a country, other than the one in which you are currently residing and/or working, or you transfer employment and/or residency after you enroll in the ESPP, the information contained herein may not be applicable to you.
United States
There are no country-specific provisions.
United Kingdom
For the avoidance of doubt, I agree that “Tax Related Items” includes any secondary class 1 (employer’s) national insurance contributions payable which may be transferred to me in relation to the acquisition of Common Stock under the ESPP and which I hereby agree to pay.
For the purpose of operating the ESPP in the European Union (including the United Kingdom after the United Kingdom leaves the European Union) the Company will collect and process information relating to you in accordance with the privacy notice which is or has been provided to you.